Jade Biosciences screens as attractively valued with a heavily favorable stated risk/reward and a stock still trading above its 200-day moving average, but that sits against below-floor quality scores, a stretched overbought reading, unusual options positioning, and a recent run of earnings misses.
Thesis pillars
- Favorable Risk Reward Skew→Stable
- Below Floor Quality Concerns→Stable
- Overbought Uptrend Above 200ma→Stable
- +2 more pillars — see the Why tab for full reasoning
Jade Biosciences, Inc. (JBIO) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $22.53: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Elevated put/call ratio: 32.75; Below-average business quality.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is... Read more
Sell if holding. Engine safety override at $22.53: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Elevated put/call ratio: 32.75; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-08Recent Developments — Jade Biosciences, Inc.
Latest news
- NEWS Jade Biosciences Enters Exclusive Worldwide License Agreement With Paragon Therapeutics; To Pay Up To $22M In Milestone — benzinga Jul 1, 2026 positive
Generated 2026-07-08T23:14:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineJADE10110-K Item 1A: 'We are substantially dependent on the success of JADE101, and our current and anticipated future clinical trials of such product candidate may not be successful.'
- MEDIUMSupplierParagon Therapeutics collaboration10-K Item 1A: 'We rely on collaborations and licensing arrangements with third parties, including Paragon Therapeutics, Inc. (“Paragon”).'
Material Events(8-K, last 90d)
- 2026-06-26Item 5.02LOWBoard appointed Mark Eisner, M.D., M.P.H. (former Vir Biotechnology CMO) as a Class I director effective June 25, 2026, and to the Nominating and Corporate Governance Committee. Routine board expansion.SEC filing →
- 2026-04-22Item 5.02LOWBoard appointed Andrew King (previously CSO/Head of R&D) as President, Research & Development effective April 18, 2026, with no compensation change. Internal promotion, not a departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $22.53: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Elevated put/call ratio: 32.75; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $20.95. Score 5.4/10, moderate confidence.
Take-profit target: $42.20 (+87.3% upside). Prior stop was $20.95. Stop-loss: $20.95.
Concentration risk — Pipeline: JADE101; Quality below floor (2.5 < 4.0).
Jade Biosciences, Inc. trades at a P/E of N/A (forward -9.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover JBIO with a consensus score of 4.4/5. Average price target: $49.
What does Jade Biosciences, Inc. do?Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology...
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.